Nile Pharmaceuticals results, Q2 2025
Net profit, assets, equity and cash flow for Q2 2025, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit78.41 millionEGP · +85.9% vs the same period a year earlier
Shareholders' equity485 millionEGP · −1.2% vs the same period a year earlier
Operating cash flow-29.32 millionEGP · −2921.6% vs the same period a year earlier
In short
- Nile Pharmaceuticals's net profit for Q2 2025 was about 78.41 million EGP, up +85.9% from 42.18 million EGP in Q2 2024.
- Operating cash flow for Q2 2025 was negative at 29.32 million EGP.
Key lines against the same period a year earlier
This periodQ2 2024Change
Net profit78.41 million42.18 million+85.9%
Gross profit484 million97.76 million+394.9%
Total assets—1.2 billion—
Total liabilities—711 million—
Shareholders' equity485 million491 million−1.2%
Total liabilities and equity1.81 billion1.2 billion+50.5%
Operating cash flow-29.32 million1.04 million−2921.6%
Investing cash flow-95.38 million-3.31 million−2778.6%
Financing cash flow129 million12.64 million+922.1%
Net change in cash—10.37 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Nile Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy